Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy. If a participant is a good fit for the study, and they enroll in the study, they will: * Visit the clinic often at the beginning of the study for physical exams, blood draws, vital signs, and other study and routine care procedures. After the first two months participants will visit the clinic every 28 days. * Take the study medications, Cirtuvivint and Olaparib. Participants will take Olaparib every day. Participants will either take Cirtuvivint 5 days per week or 2 days per week.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku co najmniej 18 lat
- •Potwierdzony nowotwór jajnika, otrzewnej lub jajnika trzonu macicy
- •Nowotwór oporny na chemię platynową (pogorszenie w ciągu 6 miesięcy od ostatniej terapii)
- •Mierzalna choroba widoczna w badaniach obrazowych
- •Wcześniejsze leczenie chemią platynową (co najmniej jeden schemat)
- •Maksymalnie 3 poprzednie linie systemowego leczenia
- •Wynik dodatni na mutację BRCA lub defekt naprawy DNA
- •Wcześniejsze leczenie inhibitorem PARP
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (2)
CU Medicine Clinics
Aurora, United States
Universtiy of Colorado Hospital
Aurora, United States
Trial contact
Kailey Palmen, BA
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.